CONFERENCE COVERAGE SERIES
Society for Neuroscience Annual Meeting 2002
Orlando, FL, U.S.A.
02 – 07 November 2002
Synapses Sizzle in Limelight of Symposium Preceding Neuroscience Conference, Orlando: Day I
It would seem intuitively appealing that the brain’s billions of minuscule information exchanges—the synapses—may be the main site of destruction in Alzheimer’s disease...
Synapses Sizzle in Limelight of Symposium Preceding Neuroscience Conference, Orlando: Day 2
The following summarizes the presentations delivered on Day 2 of the Neuroscience Conference in Orlando...
Orlando Conference: Hyperphosphorylation—It's Not Just Tau's Problem Anymore; APP, Too?
Regulated intramembranous proteolysis, RIP for short, denotes an unusual way of cutting proteins lodged in a membrane right inside their membrane-spanning parts...
Orlando: Adding to ADDLs: Where Are They; What Might They Be Doing?
As the amyloid pathology is shifting away from blaming predominantly amyloid plaques to now pointing a second accusing finger to smaller, non-deposited aggregates of the Aβ peptide...
Orlando: New Rat Model Suggests Aβ Alone, Not APP, Is Bad for Rat Smarts
Today at the Society for Neuroscience Conference, <strong>Ross Bland’s</strong> poster about a new rat model for the study of Alzheimer’s disease drew quite a crowd...
Orlando Conference: The Chicken <I>and</I> the Egg
Aβ levels and amyloid plaque load can be reduced significantly in animal models of Alzheimer's disease by interfering—either genetically or pharmacologically—with the immunoregulatory molecule CD40 ligand...
Orlando: Eyeballing the Eye in the Hunt for That Elusive Prize, an AD Biomarker
Today at the annual meeting of the Society for Neuroscience, <strong>Lee Goldstein</strong> of Massachusetts General Hospital presented evidence suggesting that the Aβ peptide occurs in the eyes of people with Alzheimer’s disease...
Orlando: It’s Not Acupuncture—LTP Is Going Parallel to Figure out Early Changes in AD
In the field’s current focus to understand what might go wrong at synapses early on in AD, measuring long-term potentiation has become a widely applied tool...
Orlando: It’s Getting Hot around CDK5, Has the Field Noticed Yet?
In a sparsely attended slide presentation yesterday at the Neuroscience meeting, <strong>Inez Vincent</strong> of the University of Washington, Seattle, presented a feat no one seems to have pulled off before...
Orlando: ADDLing Pieces to the Amyloid Puzzle; Oligomers Increase in AD Brain
In three posters on Wednesday here at the annual Neuroscience meeting, <strong>William Klein's</strong> laboratory extended their earlier presentation to add new pieces to the puzzle of the amyloid cascade hypothesis...
Orlando: ARF Awards 2002
It may not be the Oscars or Nobel prize, but recipients of the second annual Alzheimer Research Forum Awards were warmly applauded at the Society for Neuroscience meeting....
Orlando: Preliminary Results of NGF Gene Therapy Trial Are Mixed
Preliminary results of the NGF gene therapy clinical trial in early-stage AD illustrate the potential promise—and pitfalls—of gene therapy for neurodegenerative diseases...
Orlando: Medium-Throughput Target Discovery Using Brain Slices
Researchers led by Don Lo of Duke University Medical Center and Cogent Neuroscience, Inc., in Durham, North Carolina, have developed a novel brain-slice platform for identifying therapeutic targets for neurodegenerative diseases...